Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have
Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have been encouraging, according to the company. Code 7228, a proprietary coated iron oxide compound, is being groomed for cardiovascular applications.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.